[EARS] Auris Medical Holding AG


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.18 Change: -0.04 (-3.28%)
Ext. hours: Change: 0 (0%)

chart EARS

Refresh chart

Strongest Trends Summary For EARS

EARS is in the medium-term down -69% in 5 months. In the long-term down -94% in 1 year and down -94% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical trials for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss, as well as for Meniere diseases; and other development programs comprising AM-102 and AM-123 that are in preclinical studies. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, and drug delivery devices and formulations for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-28.09% ROE-34.72% ROI
Current Ratio5.77 Quick Ratio Long Term Debt/Equity Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10 K Cash From Investing Activities10 K Cash From Operating Activities-6.34 M Gross Profit
Net Profit-8.05 M Operating Profit-7.16 M Total Assets52.04 M Total Current Assets50.35 M
Total Current Liabilities5 M Total Debt Total Liabilities6.96 M Total Revenue
Technical Data
High 52 week5.3 Low 52 week0.24 Last close0.44 Last change-5.81%
RSI58 Average true range0.06 Beta0.68 Volume51.3 K
Simple moving average 20 days2.24% Simple moving average 50 days-18.09% Simple moving average 200 days-41.15%
Performance Data
Performance Week-4.78% Performance Month0.69% Performance Quart-68.26% Performance Half59.21%
Performance Year-91.02% Performance Year-to-date-3.95% Volatility daily8.12% Volatility weekly18.15%
Volatility monthly37.2% Volatility yearly128.88% Relative Volume108.2% Average Volume4.12 M
New High New Low


2019-03-14 21:48:25 | Auris Medical Announces 20-F Filing

2019-03-14 14:30:00 | These Four Healthcare Stocks Could Test March Highs

2019-03-14 07:58:25 | Auris: 4Q Earnings Snapshot

2019-03-14 07:00:45 | Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-11 08:51:05 | Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal

2019-03-07 08:01:14 | Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14, 2019

2019-02-13 10:42:25 | Case of Mistaken Identity Sends Auris Medical Shares Soaring 30%

2019-02-08 17:00:42 | Auris Medical Announces Receipt of Nasdaq Notice

2019-02-01 07:31:08 | Auris Medical Announces Full Repayment of Hercules Loan Facility

2019-01-29 07:31:00 | Auris Medical to Redomicile Holding Company from Switzerland to Bermuda

2019-01-23 09:45:00 | 4 Healthcare Stocks Making Moves On Wednesday 1/23/19

2019-01-23 08:31:00 | Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine in Promoting the Restoration of Forgotten Memories in Mice and Healthy Volunteers

2019-01-15 08:31:06 | Auris Medical Provides Update on Intranasal Betahistine Programs

2018-12-06 09:15:00 | New Healthcare Trends Pushing Stocks Higher On Thursday

2018-12-06 07:31:08 | Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine

2018-11-26 09:00:00 | Biotech and Cannabis Stocks to Watch

2018-11-23 07:40:00 | Detailed Research: Economic Perspectives on Wingstop, Marlin Business Services, Aware, Zynerba Pharmaceuticals, Auris Medical Holding AG, and Gulf Island Fabrication — What Drives Growth in Today's Competitive Landscape

2018-11-20 09:20:56 | Auris Medical Announces Results of Pre-IND Meeting With FDA For AM-201 Program in Olanzapine-Induced Weight Gain

2018-11-15 07:22:31 | Auris: 3Q Earnings Snapshot

2018-11-15 06:45:51 | Auris Medical Reports Third Quarter 2018 Financial Results and Provides Business Update

2018-11-08 07:00:41 | Auris Medical to Report Third Quarter 2018 Financial Results and Provide Business Update on Thursday, November 15, 2018

2018-11-01 12:00:25 | Edison issues initiation on Auris Medical Holding EARS

2018-10-17 06:45:57 | Auris Medical Announces Positive Results From Second Phase 1 Clinical Trial With Intranasal Betahistine

2018-10-16 08:00:00 | Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Agile Therapeutics

2018-10-15 16:32:10 | Why Auris Medical Stock Is Soaring Today

2018-10-12 07:30:55 | Auris Medical to provide update on intranasal betahistine program on Wednesday, October 17, 2018

2018-10-09 08:10:00 | Auris Medical Shares Gain on Initiated Coverage, Analysts Review and Target

2018-10-09 08:00:00 | Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Menlo Therapeutics

2018-08-30 08:16:05 | Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss

2018-08-30 08:00:00 | Today's Research Reports on Trending Tickers: Microsoft and Tableau Software

2018-08-15 06:59:22 | Auris: 2Q Earnings Snapshot

2018-08-15 06:45:57 | Auris Medical Reports Second Quarter 2018 Financial Results and Provides Business Update

2018-08-09 08:01:03 | Auris Medical to Report Second Quarter 2018 Financial Results and Provide Business and Update on Wednesday, August 15, 2018

2018-07-13 07:40:00 | Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks

2018-07-12 20:00:14 | Auris Medical Prices $7 Million Public Offering

2018-07-03 08:01:11 | Auris Medical Announces Publication Confirming Dose-Dependent Effects of Betahistine and Relationship to Bioavailability in Cat Model of Acute Vertigo

2018-06-13 07:05:00 | Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities

2018-06-04 12:34:20 | What Are The Drivers Of Auris Medical Holding AG’s NASDAQ:EARS Risks?

2018-05-30 07:45:56 | Auris Medical to Host Key Opinion Leader Call Focused on AM-201 Program for Treating Major Side Effects of Antipsychotics on June 11, 2018

2018-05-15 18:02:30 | Edited Transcript of EARS earnings conference call or presentation 15-May-18 12:00pm GMT

2018-05-15 06:56:18 | Auris: 1Q Earnings Snapshot

2018-05-15 06:45:50 | Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results

2018-05-14 07:30:42 | Auris Medical to Report First Quarter 2018 Financial Results and Provide Business and Strategy Update on Tuesday, May 15, 2018

2018-05-08 07:30:00 | Wired News – Auris Medical Reported Publication Related to AM-111 in Peer-Reviewed Scientific Journal Hearing Research

2018-05-07 09:05:35 | Benzinga Pro's 5 Stocks To Watch Today

2018-05-07 07:30:46 | Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111

2018-05-04 06:45:51 | Auris Medical Announces Publication Related to AM-111 in Peer-Reviewed Scientific Journal

2018-04-09 06:45:51 | Auris Medical Announces Early Repayment of Part of its Loan Facility

2018-04-02 07:30:00 | Blog Exposure - Actinium Announces Collaboration with Astellas Pharma

2018-03-29 07:01:11 | Auris Regains Compliance with Nasdaq's Minimum Bid Price Requirement